Skip to main content

Table 2 Absolute risk differences between 1-day and 3-day DEX intervention arms for efficacy end points

From: Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence

End point

Absolute RD (%)

95% CI

P for overall effect

P for heterogeneity

All studies

 CR, acute period

0

−2 to 3

0.87

0.61

 CR, delayed period

−1

−5 to 3

0.64

0.82

 CP, acute period

0

−3 to 3

0.84

0.56

 CP, delayed period

−4

−8 to 1

0.10

0.89

 TC, acute period

1

−3 to 4

0.72

0.64

 TC, delayed period

−2

−6 to 3

0.40

0.86

MEC studiesa

 CR, acute period

1

−2 to 5

0.38

0.56

 CR, delayed period

−2

−9 to 4

0.48

0.75

 CP, acute period

1

−4 to 5

0.74

0.25

 CP, delayed period

−2

−9 to 4

0.51

0.69

 TC, acute period

0

−5 to 6

0.90

0.31

 TC, delayed period

0

−8 to 7

0.89

0.59

AC studies

 CR, acute period

−2

−6 to 2

0.36

0.50

 CR, delayed period

0

−5 to 5

0.94

0.53

 CP, acute period

0

−6 to 5

0.87

0.52

 CP, delayed period

−4

−10 to 1

0.11

0.76

 TC, acute period

1

−5 to 7

0.69

0.73

 TC, delayed period

−3

−8 to 3

0.34

0.79

Studies without an NK1-RA

 CR, acute period

1

−2 to 5

0.37

0.77

 CR, delayed period

−3

−8 to 3

0.35

0.87

 CP, acute period

1

−3 to 5

0.59

0.33

 CP, delayed period

−3

−9 to 3

0.29

0.79

 TC, acute period

0

−5 to 5

0.99

0.45

 TC, delayed period

0

−6 to 6

0.87

0.75

Studies with an NK-1RAb

 CR, acute period

−3

−8 to 2

0.27

0.38

 CR, delayed period

1

−5 to 6

0.83

0.42

 CP, acute period

−2

−8 to 4

0.55

0.48

 CP, delayed period

−4

−10 to 2

0.19

0.56

 TC, acute period

2

−4 to 9

0.51

0.61

 TC, delayed period

−3

−10 to 3

0.29

0.62

Mixed studies

 CR, acute period

3

−2 to 8

0.23

0.32

 CR, delayed period

−1

−8 to 7

0.85

0.47

 CP, acute period

3

−2 to 9

0.26

0.24

 CP, delayed period

−1

−8 to 7

0.86

0.39

 TC, acute period

2

−7 to 11

0.64

0.19

 TC, delayed period

2

−6 to 11

0.59

1.00

Only-women studies

 CR, acute period

−1

−4 to 2

0.55

0.75

 CR, delayed period

−1

−5 to 3

0.66

0.67

 CP, acute period

−1

−5 to 2

0.48

0.75

 CP, delayed period

−5

−10 to 0

0.06

0.92

 TC, acute period

0

−4 to 5

0.91

0.65

 TC, delayed period

−1

−6 to 4

0.62

0.39

  1. Abbreviations: DEX dexamethasone, RD risk difference, CI confidence interval, CR complete response, CP complete protection, TC total control, MEC moderately emetogenic chemotherapy, AC anthracycline and cyclophosphamide, NK-1RA neurokinin-1 receptor antagonist
  2. aall patients received chemotherapy regimens classified as MEC
  3. ball patients received the combination of AC
  4. A RD below 0 (negative absolute difference) favours the 3-day DEX intervention arm and a RD above 0 (positive absolute difference) favours the 1-day DEX intervention arm
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us